A5019671119- Ovarian function and disorders
- Reproductive Biology and Fertility
- Assisted Reproductive Technology and Twin Pregnancy
- Reproductive Health and Technologies
- Reproductive System and Pregnancy
- Ectopic Pregnancy Diagnosis and Management
- Prenatal Screening and Diagnostics
- Endometriosis Research and Treatment
- Sperm and Testicular Function
- Gynecological conditions and treatments
- Reproductive Health and Contraception
- Hormonal and reproductive studies
- Pregnancy and preeclampsia studies
- Reproductive Physiology in Livestock
- Ovarian cancer diagnosis and treatment
- Sexual Differentiation and Disorders
- Estrogen and related hormone effects
- Hypothalamic control of reproductive hormones
- Genetic Syndromes and Imprinting
- Ethics and Legal Issues in Pediatric Healthcare
- Growth Hormone and Insulin-like Growth Factors
- Congenital Anomalies and Fetal Surgery
- Chemical Safety and Risk Management
- Educational Outcomes and Influences
- Organ Donation and Transplantation
University of Groningen
2025
Instituto de Investigación Sanitaria La Fe
2009-2024
Valencian Infertility Institute
2015-2024
Digital Research Alliance of Canada
2023
Guardia Civil
2007-2020
Universitat de València
2008-2020
Universidade de Vigo
2013
IVI Madrid Clinic
2013
London Bridge Hospital
2011
Radboud University Nijmegen
2011
The influence of elevated serum progesterone levels during in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles on pregnancy rates is a matter continued debate among fertility clinicians. Efforts to resolve this question have been impeded by the various assays used measure and different, arbitrary threshold values for defining 'high' levels. A non-interventional, retrospective, observational, single-centre cohort study evaluated relationship between day human chorionic...
Abstract STUDY QUESTION What is the recommended management of ovarian stimulation, based on best available evidence in literature? SUMMARY ANSWER The guideline development group formulated 84 recommendations answering 18 key questions stimulation. WHAT IS KNOWN ALREADY Ovarian stimulation for IVF/ICSI has been discussed briefly National Institute Health and Care Excellence fertility problems, Royal Australian New Zealand College Obstetricians Gynaecologist published a statement assisted...
Elevated serum progesterone levels at the end of follicular phase in controlled ovarian stimulation (COS) leads to a poorer ongoing pregnancy rate IVF cycles due reduced endometrial receptivity. The objective this study was use microarray technology compare gene expression profiles window implantation according circulating progesterone. For prospective cohort study, data were obtained from biopsies 12 young healthy oocyte donors undergoing COS with pituitary suppression by either...
Abstract STUDY QUESTION What is the recommended management for couples presenting with unexplained infertility (UI), based on best available evidence in literature? SUMMARY ANSWER The evidence-based guideline UI makes 52 recommendations definition, diagnosis, and treatment of UI. WHAT IS KNOWN ALREADY diagnosed absence any abnormalities female male reproductive systems after ‘standard’ investigations. However, a consensual standardization diagnostic work-up still lacking. traditionally...
Several evidences indicate that premature luteinization (PL) may affect IVF outcome. The primary end-point of the present study was to verify effect PL on pregnancy rate (PR) our oocyte-donation programme.PL defined as serum progesterone > or = 1.2 ng/ml day HCG. We analysed retrospectively 240 cycles in which 120 women donated twice, with first donation cycle and no following one, acting its own control. Recipients (n 240) were divided two groups according presence 120) not 120). Both...
The impact of advancing age on uterine receptiveness has always been a concern the medical establishment. Oocyte donation (OD) is perfect model for ascertaining extent this relationship, but literature somewhat unreliable, mainly due to limited samples which studies are based and insufficient control important variables such as embryo quality.The present work was developed in private infertility clinic.We retrospectively evaluate results 3089 OD cycles that ended up d 3 transfer. Severe male...
ObjectiveTo evaluate the dose–response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study influence initial antimüllerian hormone (AMH) concentrations.DesignRandomized, controlled, assessor-blinded, AMH-stratified (low: 5.0–14.9 pmol/L [0.7–<2.1 ng/mL]; high: 15.0–44.9 [2.1–6.3 ng/mL]) trial.SettingSeven infertility centers four countries.Patient(s)Two...
Abstract STUDY QUESTION Is there a serum progesterone (P) threshold on the day of embryo transfer (ET) in artificial endometrium preparation cycles below which chances ongoing pregnancy are reduced? SUMMARY ANSWER Serum P levels &lt;8.8 ng/ml ET lower rate (OPR) both own or donated oocyte cycles. WHAT IS KNOWN ALREADY We previously found that &lt;9.2 significantly decrease OPR sample 211 donation recipients. Here, we assessed whether these results applicable to all infertile patients...
This descriptive study evaluates the impact on endometrial development of standard and high doses a GnRH antagonist in stimulated cycles compared with agonist natural cycles.Thirty-one oocyte donors were treated combination rFSH 0.25 mg/day ganirelix (standard dose), 2 (high dose) or 0.6 buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered luteal phase. Endometrial biopsies performed 7 days after HCG administration. Additional carried out subset 12 subjects,...
Highly purified hMG (hp-hMG) has recently shown better cycle outcome than the recombinant FSH (rFSH) when compared in GnRH agonist long protocol cycles. However, they have not yet been antagonist cycles.A RCT comparing ongoing pregnancy rate (primary end-point) 280 patients undergoing IVF/ICSI after stimulation with hp-hMG or rFSH controlled a antagonist.No significant differences were observed between and terms of per started (35.0 versus 32.1%, respectively; P = 0.61); relative risk: 1.09...
ObjectiveTo evaluate a new fully automated assay measuring antimüllerian hormone (AMH; Roche Elecsys) against antral follicle count in women of reproductive age.DesignProspective cohort study.SettingHospital infertility clinics and academic centers.Patient(s)Four hundred fifty-one aged 18 to 44 years, with regular menstrual cycles.Intervention(s)None.Main Outcome Measure(s)AMH (AFC) determined at single visit on day 2–4 the cycle.Result(s)There was statistically significant variance AFC but...